



25 June 2024

cyclo**medica**
techne**gas**

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

CYCLOPHARM COMPLETES OVERSUBSCRIBED SHARE PURCHASE PLAN TO RAISE \$4 MILLION

- **Share Purchase Plan (SPP) seeking to raise \$2 million closes at \$4 million following strong shareholder support**
 - **Follows successful institutional Placement which raised \$20 million in May**
 - **Cyclopharm is now fully funded to accelerate manufacture and sales of Technegas® following USFDA approval together with the recent US reimbursement granted**
-

Cyclopharm Limited (**ASX:CYC**) today announced that following strong support from eligible shareholders, the CYC board has exercised its discretion to increase the size of its SPP, closing the offer at \$4.0 million compared with its original target of \$2.0 million.

A total of 2,932,435 new fully paid CYC ordinary shares (SPP Shares) are expected to be issued to successful applicants on Friday, 28 June 2024 at an issue price of \$1.42 per SPP Share, representing approximately 2.64% of CYC's updated ordinary shares on issue.

The SPP issue price is equivalent to the price paid by institutional and sophisticated investors under the Placement launched last month by CYC in conjunction with this SPP. The only applicants to not receive their full allocation requests in the SPP were those who lodged more than one offer and whose totals exceeded the maximum \$30,000.

Cyclopharm's Managing Director, James McBrayer said, "We are pleased to provide all eligible shareholders with the opportunity to participate in this offer. Exceptional interest has allowed us to double its size by an additional \$2.0 million, and like our recently completed share Placement, we appreciate the support this oversubscription demonstrates."

"Our shareholders have many choices about where they invest and the success of our recent capital initiatives ensures we are fully funded to maximise our growth opportunities."

The SPP offer was made to approximately 1,500 eligible shareholders. Applications were submitted by approximately 275 eligible shareholders for a total value of approximately \$4.17 million. The response represented a participation rate of approximately 18% of eligible shareholders, with an average application amount of approximately \$15,200.

The new shares are expected to be allotted on Friday, 28 June 2024 and quoted on ASX on Monday, 1 July 2024. Refunds applications where relevant are expected to be made as soon as practical after the New Shares are issued. SPP Shares will rank equally with existing fully paid CYC ordinary shares from their date of issue.

- ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director and CEO.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®

The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnace for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

In the United States the Technegas approved indication for use for use is:

TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older is for the visualization of pulmonary ventilation and the evaluation of pulmonary embolism when paired with perfusion imaging.